Long Term Growth Prospects From BioSante and Avanir Pharmaceuticals Remain Bright
The Paragon Report Provides Equity Research on BioSante & Avanir Pharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 09/19/11 -- The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:
In recent years the FDA has been heavily scrutinized for making the approval process more difficult for drug developers. A groundbreaking study released this year by the BIO and BioMedTracker finds that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is a mere ten percent. Previously the rate of approval was one in five to one in six. Oncology drugs faced the toughest road to approval despite the fact that the disease area is the most closely studied in all of drug development.
Janet Woodcock, the head of the FDA's drug division, is quick to dismiss concerns regarding the FDA's approval process. This summer in testimony before the House Energy and Commerce's health subcommittee, Woodcock explained the agency meets more than 90% of deadlines that are part of the drug-review process. She also said so-called first cycle approvals are at a 20-year high with and said more than two-thirds of new drugs being approved within the six-to-10-month time frames given to new drug applications.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
BioSante is currently running three late-stage clinical trials of LibiGel, a female sexual dysfunction treatment. The company plans to file a new marketing application in early 2012. In June, BioSante said it had stopped enrolling patients in a safety trial because a data analysis indicated a 90-percent chance the drug would meet its goal.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Avanir began selling Nuedexta in February. The drug is approved as a treatment for pseudobulbar affect, a condition that involves involuntary emotional outbursts like laughing or crying. It is associated with brain disease or injury.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at .
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.09.2011 - 06:16 Uhr
Sprache: Deutsch
News-ID 1038482
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Commercial & Investment Banking
Anmerkungen:
Diese Pressemitteilung wurde bisher 67 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Long Term Growth Prospects From BioSante and Avanir Pharmaceuticals Remain Bright
"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
